Stay updated on Filgotinib and Lanraplenib in Female CLE Clinical Trial
Sign up to get notified when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.

Latest updates to the Filgotinib and Lanraplenib in Female CLE Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe page revision updated from v3.6.4 to v3.6.5, indicating a small backend/template update rather than substantive changes to visible content.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4, reflecting a minor version update to the page metadata rather than substantive changes to the study details.SummaryDifference0.0%

- Check53 days agoChange DetectedThe page shows a new revision label, updating from Revision: v3.6.0 to Revision: v3.6.3, reflecting a newer site release. This update appears to be a software revision rather than a change to the study data or page content.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page adds new help sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment notice indicating no participants are being sought. It also updates the Intervention/Treatment label formatting and the site revision from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check74 days agoChange DetectedThe page now shows a new software revision label (v3.5.5) in place of the previous one (v3.5.4), reflecting a software version update to the page rendering.SummaryDifference0.0%

- Check89 days agoChange DetectedLakefront Biotherapeutics NV was added as a collaborator and Galapagos NV was removed from the study's Collaborators and Investigators list.SummaryDifference0.0%

Stay in the know with updates to Filgotinib and Lanraplenib in Female CLE Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib and Lanraplenib in Female CLE Clinical Trial page.